Erythema Multiforme, Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis

Rook's Textbook of Dermatology: Eighth Edition

Volumn 4, Issue , 2010, Pages 4065-4086

  Breathnach, Stephen M ^a,b  

^a ST THOMAS HOSPITAL   (United Kingdom)

^b EPSOM AND ST HELIER UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

Author keywords

Aseptic pustules of acute generalized exanthematous pustulosis (AGEP); Drugs implicated in Stevens Johnson syndrome; Erythema multiforme having an immunological basis; Erythema multiforme involving macular, papular or urticarial lesions; Erythema multiforme, Stevens Johnson syndrome and toxic epidermal necrolysis; Management of TEN in dermatology intensive care unit or a burns unit; Pathology changes in upper dermis and lower epidermis; Stevens Johnson syndrome and toxic epidermal necrolysis; Toxic shock syndrome, occurring in menstruating women

Indexed keywords

EID: 84888672531     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9781444317633.ch76     Document Type: Chapter

References (503)

1. Stevens AH, Johnson FC. A new eruptive fever associated with stomatitis and ophthalmia: report of two cases in children. Am J Dis Child 1922; 24: 526-7.
2. Côté B, Wechsler J, Bastuji-Garin S et al. Clinicopathologic correlation in erythema multiforme and Stevens-Johnson syndrome. Arch Dermatol 1995; 131: 1268-72.
3. Lyell A. Toxic epidermal necrolysis: an eruption resembling scalding of the skin. Br J Dermatol 1956; 68: 355-61.
4. Revuz JE, Roujeau JC. Advances in toxic epidermal necrolysis. Semin Cutan Med Surg 1996; 15: 258-66.
5. Wolkenstein P, Revuz J. Toxic epidermal necrolysis. Dermatol Clin 2000; 18: 485-95, ix.
6. Bastuji-Garin S, Rzany B, Stern RS et al. A clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme. Arch Dermatol 1993; 129: 92-6.
7. Roujeau JC. The spectrum of Stevens-Johnson syndrome and toxic epidermal necrolysis: a clinical classification. J Invest Dermatol 1994; 102: 28S-30S.
8. Assier H, Bastuji-Garin S, Revuz J, Roujeau JC. Erythema multiforme with mucous membrane involvement and Stevens-Johnson syndrome are clinically different disorders with distinct causes. Arch Dermatol 1995; 131: 539-43.
9. Roujeau JC. Stevens-Johnson syndrome and toxic epidermal necrolysis are severity variants of the same disease which differs from erythema multiforme. J Dermatol 1997; 24: 726-9.
10. Auquier-Dunant A, Mockenhaupt M, Naldi L et al. Correlations between clinical patterns and causes of erythema multiforme majus, Stevens-Johnson syndrome, and toxic epidermal necrolysis: results of an international prospective study. Arch Dermatol 2002; 138: 1019-24.
11. Stern RS, Albengres E, Carlson J et al. An international comparison of case definition of severe adverse cutaneous reactions to medicines. Drug Saf 1993; 8: 69-77.
12. Ruiz-Maldonado R. Acute disseminated epidermal necrosis types 1, 2, and 3: study of 60 cases. J Am Acad Dermatol 1985; 13: 623-35.
13. Lyell A. Requiem for toxic epidermal necrolysis. Br J Dermatol 1990; 122: 837-8.
14. Duvic M, Reisner EG, Dawson DV et al. HLA-B15 associates with erythema multiforme. J Am Acad Dermatol 1983; 8: 493-6.
15. Kämpgen E, Burg G, Wank R. Association of herpes simplex virus-induced erythema multiforme with the human leucocyte antigen Dqw3. Arch Dermatol 1988; 124: 1372-5.
16. Schofield JK, Tatnall FM, Brown J et al. Recurrent erythema multiforme: tissue typing in a large series of patients. Br J Dermatol 1994; 131: 532-5.
17. Bushkell LL, Mackel SE, Jordan RE. Erythema multiforme: direct immunofluorescence studies and detection of circulating immune complexes. J Invest Dermatol 1980; 74: 372-4.
18. Kazmierowski JA, Wuepper KD. Erythema multiforme: clinical spectrum and immunopathogenesis. Springer Semin Immunopathol 1981; 4: 45-53.
19. Matsuoka LY, Wortsmann J, Stanley JR. Epidermal autoantibodies in erythema multiforme. J Am Acad Dermatol 1989; 21: 677-80.
20. Foedinger D, Stericzky B, Elbe A et al. Autoantibodies against desmoplakin I and II define a subset of patients with erythema multiforme major. J Invest Dermatol 1996; 106: 1012-6.
21. Fukiwake N, Moroi Y, Urabe K et al. Detection of autoantibodies to desmoplakin in a patient with oral erythema multiforme. Eur J Dermatol 2007; 17: 238-41.
22. Larcher C, Gasser A, Hattmannstorfer R et al. Interaction of HSV-1 infected peripheral blood mononuclear cells with cultured dermal microvascular endothelial cells: a potential model for the pathogenesis of HSV-1 induced erythema multiforme. J Invest Dermatol 2001; 116: 150-6.
23. Brice S, Krzemien D, Weston W et al. Detection of herpes simplex virus DNA in cutaneous lesions of erythema multiforme. J Invest Dermatol 1989; 93: 183-7.
24. Aslanzadeh J, Helm KF, Espy MJ et al. Detection of HSV-specific DNA in biopsy of patients with erythema multiforme by polymerase chain reaction. Br J Dermatol 1992; 126: 19-23.
25. Aurelian L, Ono F, Burnett J. Herpes simplex virus (HSV)-associated erythema multiforme (HAEM): a viral disease with an autoimmune component. Dermatol Online J 2003; 9: 1.
26. Ono F, Sharma BK, Smith CC et al. CD34+ cells in the peripheral blood transport herpes simplex virus DNA fragments to the skin of patients with erythema multiforme (HAEM). J Invest Dermatol 2005; 124: 1215-24.
27. Gober MD, Laing JM, Burnett JW, Aurelian L. The Herpes simplex virus gene Pol expressed in herpes-associated erythema multiforme lesions upregulates/ activates SP1 and inflammatory cytokines. Dermatology 2007; 215: 97-106.
28. Bruynzeel L, Van der Raaij EMH, Boorsma DM et al. Increased adherence to keratinocytes of peripheral blood mononuclear leucocytes of a patient with drug-induced erythema multiforme. Br J Dermatol 1992; 129: 45-9.
29. Inachi S, Mizutani H, Shimizu M. Epidermal apoptotic cell death in erythema multiforme and Stevens-Johnson syndrome: contribution of perforin-positive cell infiltration. Arch Dermatol 1997; 133: 845-9.
30. Spandau U, Brocker EB, Kampgen E, Gillitzer R. CC and CXC chemokines are differentially expressed in erythema multiforme in vivo. Arch Dermatol 2002; 138: 1027-33.
31. Anderson JA, Bolin V, Sutow WW et al. Virus as possible aetiologic agent of erythema multiforme exudativum, bullous type. Arch Dermatol Syphilol 1949; 59: 251-62.
32. Editorial. Recurrent erythema multiforme and herpes simplex virus. Lancet 1989; ii: 1311-2.
33. Schofield JK, Tatnall FM, Leigh IM. Recurrent erythema multiforme: clinical features and treatment in a large series of patients. Br J Dermatol 1992; 128: 542-5.
34. Sontheimer RD, Garibaldi RA, Kruegger GG. Stevens-Johnson syndrome associated with Mycoplasma pneumoniae infections. Arch Dermatol 1978; 114: 241-4.
35. Grosber M, Alexandre M, Poszepczynska-Guigné E et al. Recurrent erythema multiforme in association with recurrent Mycoplasma pneumoniae infections. J Am Acad Dermatol 2007; 56 (5 Suppl.): S118-9.
36. Strom J. Febrile mucocutaneous syndromes (ectodermosis erosiva pleuriorificialis, Stevens-Johnson syndrome, etc.) in adenovirus infections. Acta Derm Venereol (Stockh) 1967; 47: 281.
37. Seishima M, Oyama Z, Yamamura M. Erythema multiforme associated with cytomegalovirus infection in non-immunosuppressed patients. Dermatology 2001; 203: 299-302.
38. Wanner M, Pol-Rodriguez M, Hinds G et al. Persistent erythema multiforme and CMV infection. J Drugs Dermatol 2007; 6: 333-6.
39. Olut AI, Erkek E, Ozunlu H, Ozsakarya F. Erythema multiforme associated with acute hepatitis B virus infection. Clin Exp Dermatol 2006; 31: 137-8.
40. Williamson DM. Erythema multiforme in infectious mononucleosis. Br J Dermatol 1974; 91: 345-6.
41. Hughes T, Burrows NP. Infectious mononucleosis presenting as erythema multiforme. Clin Exp Dermatol 1993; 18: 373-4.
42. Schmidt E, Weissbrich B, Bröcker EB et al. Orf followed by erythema multiforme. J Eur Acad Dermatol Venereol 2006; 20: 612-3.
43. Prais D, Grisuru-Soen G, Barzilai A, Amir J. Varicella zoster virus infection associated with erythema multiforme in children. Infection 2001; 29: 37-9.
44. Lang MH, Wehrenberg O. Erythema exsudativum multiforme bei Rickettsiose. Hautarzt 1987; 38: 432-4.
45. Salim A, Young E. Erythema multiforme associated with Trichophyton mentagrophytes infection. J Eur Acad Dermatol Venereol 2002; 16: 645-6.
46. Gilaberte Y, Coscojuela C, García-Prats MD, Mairal MP. Erythema multiforme associated with inflammatory ringworm on the hand. Br J Dermatol 2003; 149: 1078-9.
47. Leznoff A, Frank H, Telner P et al. Histoplasmosis in Montreal during the fall of 1963, with observations on erythema multiforme. Can Med Assoc J 1963; 91: 1154-60.
48. Sellers TF, Price WN, Newberry WM. An epidemic of erythema multiforme and erythema nodosum caused by histoplasmosis. Ann Intern Med 1965; 62: 1244-62.
49. Warin AP. Case 2: diagnosis-erythema multiforme as a presentation of autoimmune progesterone dermatitis. Clin Exp Dermatol 2001; 26: 107-8.
50. Carswell WA. A case of sarcoidosis presenting with erythema multiforme. Am Rev Respir Dis 1972; 106: 462-4.
51. Davis J, Pack GT. Erythema multiforme following deep X-ray therapy. Arch Dermatol Syphilol 1952; 66: 41-8.
52. Nawalkjha PL, Mathur NK, Malhotra YK et al. Severe erythema multiforme (Stevens-Johnson syndrome) following telecobalt therapy. Br J Radiol 1972; 45: 768-9.
53. Yoshitake T, Nakamura K, Shioyama Y et al. Erythema multiforme and Stevens- Johnson syndrome following radiotherapy. Radiat Med 2007; 25: 27-30.
54. Fraser-Andrews EA, Morris-Jones R, Novakovic L, Hawk JL. Erythema multiforme following polymorphic light eruption: a report of two cases. Clin Exp Dermatol 2005; 30: 232-4.
55. Kauppinen K. Cutaneous reactions to drugs: with special reference to severe mucocutaneous bullous eruptions and sulphonamides. Acta Derm Venereol (Stockh) 1972; 52 (Suppl. 68): 1-89.
56. Huff JC, Weston WL, Tonnesen MG. Erythema multiforme. a critical review of characteristics, diagnostic criteria, and causes. J Am Acad Dermatol 1983; 8: 763-75.
57. Stewart MG, Duncan NO III, Franklin DJ et al. Head and neck manifestations of erythema multiforme in children. Otolaryngol Head Neck Surg 1994; 111: 236-42.
58. Gebel K, Hornstein OP. Drug-induced oral erythema multiforme: results of a long-term retrospective study. Dermatologica 1984; 168: 35-40.
59. Nethercott JR, Choi BC. Erythema multiforme (Stevens-Johnson syndrome): chart review of 123 hospitalized patients. Dermatologica 1985; 171: 383-96.
60. Fabbri P, Panconesi E. Erythema multiforme ('minus' and 'maius') and drug intake. Clin Dermatol 1993; 11: 479-89.
61. Rzany B, Hering O, Mockenhaupt M et al. Histopathological and epidemiological characteristics of patients with erythema exudativum multiforme major, Stevens-Johnson syndrome and toxic epidermal necrolysis. Br J Dermatol 1996; 135: 6-11.
62. Oh SW, Lew W. Erythema multiforme induced by acetaminophen: a recurrence at distant sites following patch testing. Contact Dermatitis 2005; 53: 56-7.
63. Ernst EJ, Egge JA. Celecoxib-induced erythema multiforme with glyburide cross-reactivity. Pharmacotherapy 2002; 22: 637-40.
64. Sarkar R, Kaur C, Kanwar AJ. Erythema multiforme due to rofecoxib. Dermatology 2002; 204: 304-5.
65. Thirion L, Nikkels AF, Piérard GE. Etoricoxib-induced erythema-multiformelike eruption. Dermatology 2008; 216: 227-8.
66. Prieto A, De Barrio M, Pérez C. Piroxicam-induced erythema multiforme. Contact Dermatitis 2004; 50: 263.
67. Perez A, Cabrerizo S, de Barrio M et al. Erythema-multiforme-like eruption from amoxycillin and allopurinol. Contact Dermatitis 2001; 44: 113-4.
68. Kumar A, Edward N, White MI et al. Allopurinol, erythema multiforme, and renal insufficiency. BMJ 1996; 312: 173-4.
69. Lin GL, Chiu CH, Lin SK. Quetiapine-induced erythema multiforme minor: a case report. J Clin Psychopharmacol 2006; 26: 668-9.
70. Desarkar P, Nizamie SH. Risperidone-induced erythema multiforme minor. Br J Clin Pharmacol 2006; 62: 504-5.
71. Balldin J, Berggren U, Heijer A, Mobacken H. Erythema multiforme caused by lithium. J Am Acad Dermatol 1991; 24: 1015-6.
72. Ford HE, Jenike MA. Erythema multiforme associated with trazadone therapy. J Clin Psychiatry 1985; 46: 294-5.
73. Gales BJ, Gales MA. Erythema multiforme and angioedema with indapamide and sertraline (Letter). Am J Hosp Pharm 1994; 51: 118-9.
74. Lineberry TW, Peters GE Jr, Bostwick JM. Bupropion-induced erythema multiforme. Mayo Clin Proc 2001; 76: 664-6.
75. Ejaz AA, Walsh JS, Wasiluk A. Erythema multiforme associated with candesartan cilexetil. South Med J 2004; 97: 614-5.
76. Burger DE, Goyal S. Erythema multiforme from metformin. Ann Pharmacother 2004; 38: 1537.
77. de Frutos C, de Barrio M, Tornero P et al. Erythema multiforme from sulfaguanidine. Contact Dermatitis 2002; 46: 186-7.
78. Peña AL, Henriquezsantana A, Gonzalez-Seco E et al. Exudative erythema multiforme induced by hydroxyzine. Eur J Dermatol 2008; 18: 194-5.
79. Horiuchi Y. Erythema multiforme caused by the H2-blocker, roxatidine. J Dermatol 2000; 27: 352-3.
80. Garty BZ, Offer I, Livni E, Danon YL. Erythema multiforme and hypersensitivity myocarditis caused by ampicillin. Ann Pharmacother 1994; 28: 730-1
81. Padial MA, Barranco P, Lopez-Serrano C. Erythema multiforme to vancomycin. Allergy 2000; 55: 1201.
82. Nettis E, Giordano D, Pierluigi T et al. Erythema multiforme-like rash in a patient sensitive to ofloxacin. Acta Derm Venereol (Stockh) 2002; 82: 395-6.
83. Pierce TH, Vig SJ, Ingram PM. Ceftazidime in the treatment of lower respiratory tract infection. J Antimicrob Chemother 1983; 12 (Suppl. A): 21-5.
84. Thami GP, Kaur S, Kanwar AJ. Erythema multiforme due to griseofulvin with positive re-exposure test. Dermatology 2001; 203: 84-5.
85. Todd P, Halpern S, Munro DD. Oral terbinafine and erythema multiforme. Clin Exp Dermatol 1995; 20: 247-8.
86. Gupta AK, Kopstein JB, Shear NH. Hypersensitivity reaction to terbinafine. J Am Acad Dermatol 1997; 36: 1018-9.
87. Katz SK, Medenica MM, Kobayashi K et al. Erythema multiforme induced by suramin. J Am Acad Dermatol 1995; 32: 292-3.
88. Remich SA, Otieno W, Polhemus ME et al. Bullous erythema multiforme after treatment with Malarone, a combination antimalarial composed of atovaquone and proguanil hydrochloride. Trop Doct 2008; 38: 190-1.
89. Scully C, Diz Dios P. Orofacial effects of antiretroviral therapies. Oral Dis 2001; 7: 205-10.
90. Borrás-Blasco J, Navarro-Ruiz A, Borrás C, Casterá E. Adverse cutaneous reactions associated with the newest antiretroviral drugs in patients with human immunodeficiency virus infection. J Antimicrob Chemother 2008; 62: 879-88.
91. Wojnarowska F, Greaves MW, Peachey RDG et al. Progesterone-induced erythema multiforme. J R Soc Med 1985; 78: 407-8.
92. Suzuki R, Matsumura Y, Kambe N et al. Erythema multiforme due to progesterone in a low-dose oral contraceptive pill. Br J Dermatol 2005; 152: 370-1.
93. Reynolds NJ, Sansom JE. Erythema multiforme during danazol therapy. Clin Exp Dermatol 1992; 17: 140.
94. Lavabre C, Chevalier X, Larget-Piet B. Erythema multiforme after intradural injection of prednisolone acetate. Br J Rheumatol 1992; 31: 717-8.
95. Sachs B, Renn C, al Masaoudi T, Merk HF. Fenoterol-induced erythema exudativum multiforme-like exanthem: demonstration of drug-specific lymphocyte reactivity in vivo and in vitro. Acta Derm Venereol 2001; 81: 368-9.
96. Hall VC, El-Azhary RA, Bouwhuis S, Rajkumar SV. Dermatologic side effects of thalidomide in patients with multiple myeloma. J Am Acad Dermatol 2003; 48: 548-52.
97. Sendur MA, Kilickap S. Stevens-Johnson syndrome after treatment with capecitabine. Clin Oncol (R Coll Radiol) 2008; 20: 202-3.
98. MacGregor JL, Silvers DN, Grossman ME, Sherman WH. Sorafenib-induced erythema multiforme. J Am Acad Dermatol 2007; 56: 527-8.
99. Blanes M, Silvestre JF, Albares MP et al. Erythema multiforme due to methotrexate reproduced with patch test. Contact Dermatitis 2005; 52: 164-5.
100. Mori T, Sato N, Watanabe R, et al. Erythema exsudativum multiforme induced by granulocyte colony-stimulating factor in an allogeneic peripheral blood stem cell donor. Bone Marrow Transplant 2000; 26: 239-40.
101. Tan WP, Goh BK, Tan SH. Extensive erythema multiforme-like eruption due to traditional Chinese herbal drug 'Dong Ling Hou Tong Pian'. Clin Exp Dermatol 2006; 31: 291-3
102. Wolfsen HC, Ng CS. Cutaneous consequences of photodynamic therapy. Cutis 2002; 69: 140-2.
103. Frederiksen MS, Brenøe E, Trier J. Erythema multiforme minor following vaccination with paediatric vaccines. Scand J Infect Dis 2004; 36: 154-5.
104. Bernardini ML, D'Angelo G, Oggiano N et al. Erythema multiforme following live attenuated trivalent measles-mumps-rubella vaccine. Acta Derm Venereol 2006; 86: 359-60.
105. Karincaoglu Y, Aki T, Erguvan-Onal R, Seyhan M. Erythema multiforme due to diphtheria-pertussis-tetanus vaccine. Pediatr Dermatol 2007; 24: 334-5.
106. Studdiford J, Oppenheim L, McCann E, Altshuler M. Erythema multiforme after meningitis vaccine: patient safety concerns with repeat immunization. Pharmacotherapy 2006; 26: 1658-61.
107. Loche F, Schwarze HP, Thedenat B et al. Erythema multiforme associated with hepatitis B immunization. Clin Exp Dermatol 2000; 25: 167-8.
108. Frey SE, Couch RB, Tacket CO et al. Clinical responses to undiluted and diluted smallpox vaccine. N Engl J Med 2002; 346: 1265-74.
109. Karakaya G, Sahin S, Fuat Kalyoncu A. Erythema multiforme: as a complication of allergen-specific immunotherapy. Allergol Immunopathol (Madr) 2001; 29: 276-8.
110. Wiedemeyer K, Enk A, Jappe U. Erythema multiforme following allergic contact dermatitis: case report and literature review. Acta Derm Venereol 2007; 87: 559-61.
111. Lengrand F, Tellart AS, Segard M et al. Erythema multiforme-like eruption: an unusual presentation of primula contact allergy. Contact Dermatitis 2001; 44: 35.
112. Bonamonte D, Filotico R, Mastrandrea V et al. Erythema multiforme-like contact dermatitis from primin. Contact Dermatitis 2008; 59: 174-6.
113. Werchniak AE, Schwarzenberger K. Poison ivy: an underreported cause of erythema multiforme. J Am Acad Dermatol 2004; 51 (5 Suppl.): S159-60.
114. Jovanovic M, Mimica-Dukic N, Poljacki M, Boza P. Erythema multiforme due to contact with weeds: a recurrence after patch testing. Contact Dermatitis 2003; 48: 17-25.
115. Athanasiadis GI, Pfab F, Klein A et al. Erythema multiforme due to contact with laurel oil. Contact Dermatitis 2007; 57: 116-8.
116. Hong SJ, Chang CH. Erythema multiforme-like generalized allergic contact dermatitis caused by Alpinia galanga. Contact Dermatitis 2006; 54: 118-20.
117. Agrup G, Cronin E. Contact dermatitis X. Br J Dermatol 1970; 82: 428-33.
118. Fisher AA. Erythema multiforme-like eruptions due to topical medications. II. Cutis 1986; 37: 158-61.
119. Perret CM, Steijlen PM, Zaun H, Happle R. Erythema multiforme-like lesions: a rare side effect of topical immunotherapy with diphenylcyclopropenone. Dermatologica 1990; 180: 5-7.
120. Stingeni L, Caraffini S, Assalve D et al. Erythema multiforme-like contact dermatitis from budesonide. Contact Dermatitis 1996; 34: 154-5.
121. Calista D, Schianchi S. Erythema multiforme-like eruption induced by contact dermatitis caused by topical corticosteroids. G Ital Dermatol Venereol 2008; 143: 227-8.
122. Newman JM, Rindler JM, Bergfeld WF. Stevens-Johnson syndrome associated with topical nitrogen mustard therapy. J Am Acad Dermatol 1997; 36: 112-4.
123. Mateo MP, Velasco M, Miquel FJ, de la Cuadra J. Erythema multiforme-like eruption following allergic contact dermatitis from sesquiterpene lactones in herbal medicine. Contact Dermatitis 1995; 33: 449-50.
124. Koch P, Bahmer FA. Erythema multiforme-like, urticarial papular and plaque eruptions from bufexamac: report of four cases. Contact Dermatitis 1994; 31: 97-101.
125. Kerre S, Busschots A, Dooms-Goossens A. Erythema multiforme-like contact dermatitis due to phenylbutazone. Contact Dermatitis 1995; 33: 213-4.
126. Silvestre JF, Betlloch I, Guijarro J et al. Erythema multiforme-like eruption on the application site of a nitroglycerin patch, followed by widespread erythema multiforme. Contact Dermatitis 2001; 45: 299-300.
127. Khanna M, Qasem K, Sasseville D. Allergic contact dermatitis to tea tree oil with erythema multiforme-like id reaction. Am J Contact Dermat 2000; 11: 238-42.
128. Balato A, Patruno C, Balato N et al. Erythema multiforme-like eruption because of para-phenylenediamine. Contact Dermatitis 2008; 58: 65-6.
129. Jappe U, Hausen BM, Petzoldt D. Erythema-multiforme-like eruption and depigmentation following allergic contact dermatitis from a paint-on henna tattoo, due to para-phenylenediamine contact hypersensitivity. Contact Dermatitis 2001; 45: 249-50.
130. Sidwell RU, Francis ND, Basarab T, Morar N. Vesicular erythema multiformelike reaction to para-phenylenediamine in a henna tattoo. Pediatr Dermatol 2008; 25: 201-4.
131. Izu K, Hino R, Isoda H et al. Photocontact dermatitis to ketoprofen presenting with erythema multiforme. Eur J Dermatol 2008; 18: 710-3.
132. Lu CY, Sun CC. Localized erythema-multiforme-like contact dermatitis from rubber gloves. Contact Dermatitis 2001; 45: 311-2.
133. Inanir I. Erythema multiforme associated with blister beetle dermatitis. Contact Dermatitis 2002; 46: 175.
134. Fisher AA. Erythema multiforme-like eruptions due to topical miscellaneous compounds. III. Cutis 1986; 37: 262-4.
135. Heras-Mendaza F, Casado-Fariñas I, Paredes-Gascón M, Conde-Salazar L. Erythema multiforme-like eruption due to an irritant contact dermatitis from a glyphosate pesticide. Contact Dermatitis 2008; 59: 54-6.
136. Hata M, Tokura Y, Takigawa M. Erythema multiforme-like eruption associated with contact dermatitis to cutting oil. Eur J Dermatol 2001; 11: 247-8.
137. Akita H, Washimi Y, Akamatsu H et al. Erythema multiforme-like occupational contact dermatitis due to bisphenol A. Contact Dermatitis 2001; 45: 305.
138. Ackerman AB. Dermal and epidermal types of erythema multiforme. Arch Dermatol 1975; 111: 795.
139. Bedi TR, Pinkus H. Histopathological spectrum of erythema multiforme. Br J Dermatol 1976; 95: 243-50.
140. Rzany B, Hering O, Mockenhaupt M et al. Histopathological and epidemiologi - cal characteristics of patients with erythema exudativum multiforme major, Stevens-Johnson syndrome and toxic epidermal necrolysis. Br J Dermatol 1996; 135: 6-11.
141. Paquet P, Pierard GE. Erythema multiforme and toxic epidermal necrolysis: a comparative study. Am J Dermatopathol 1997; 19: 127-32.
142. Lozada-Nur F, Gorsky M, Silverman S. Oral erythema multiforme: clinical observation and treatment of 95 patients. Oral Surg Oral Med Oral Pathol 1989; 67: 36-40.
143. Huff JC, Weston WL. Recurrent erythema multiforme. Medicine 1989; 68: 133-40.
144. Huff JC, Weston WL, Tonnesen MG. Erythema multiforme: a critical review of characteristics, diagnostic criteria and causes. J Am Acad Dermatol 1983; 8: 763-75.
145. Bastuji-Garin S, Rzany B, Stern RS et al. A clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme. Arch Dermatol 1993; 129: 92-6.
146. Auquier-Dunant A, Mockenhaupt M, Naldi L et al. Correlations between clinical patterns and causes of erythema multiforme majus, Stevens-Johnson syndrome, and toxic epidermal necrolysis: results of an international prospective study. Arch Dermatol 2002; 138: 1019-24.
147. Johnston GA, Ghura HS, Carter E, Graham-Brown RA. Neonatal erythema multiforme major. Clin Exp Dermatol 2002; 27: 661-4.
148. Torrelo A, Moreno M, De Prada I et al. Erythema multiforme in a neonate. J Am Acad Dermatol 2003; 48 (Suppl. 5): 78-9.
149. Rasmussen JE. Erythema multiforme in children. Br J Dermatol 1976; 95: 181-6.
150. Murphy GM. Diseases associated with photosensitivity. J Photochem Photobiol B 2001; 64: 93-8.
151. Lin JH, Sheu HM, Lee JY. Acute generalized exanthematous pustulosis with erythema multiforme-like lesions. Eur J Dermatol 2002; 12: 475-8.
152. Drago F, Parodi A, Rebora A. Persistent erythema multiforme: report of new cases and review of the literature. J Am Acad Dermatol 1995; 33: 366-9.
153. Pavlovic MD, Karadaglic DM, Kandolf LO, Mijuskovic ZP. Persistent erythema multiforme: a report of three cases. J Eur Acad Dermatol Venereol 2001; 15: 54-8.
154. Micalizzi C, Farris A. Erythema multiforme along Blaschko's lines. J Eur Acad Dermatol Venereol 2000; 14: 203-4.
155. Abraham Z, Feuerman EJ, Schafer I, Feinmesser M. Disseminated granuloma annulare following erythema multiforme minor. Australas J Dermatol 2000; 41: 238-41.
156. Rowell NR, Beck JS, Anderson JR. Lupus erythematosus and erythema multiforme- like lesions. Arch Dermatol 1963; 88: 176-80.
157. Zeitouni NC, Funaro D, Cloutier RA et al. Redefining Rowell's syndrome. Br J Dermatol 2000; 142: 343-6.
158. Shteyngarts AR, Warner MR, Camisa C. Lupus erythematosus associated with erythema multiforme: does Rowell's syndrome exist? J Am Acad Dermatol 1999; 40: 773-7.
159. Aydogan K, Karadogan S, Balaban Adim S, Tunali S. Lupus erythematosus associated with erythema multiforme: report of two cases and review of the literature. J Eur Acad Dermatol Venereol 2005; 19: 621-7.
160. Shadid NH, Thissen CA, van Marion AM et al. Lupus erythematosus associated with erythema multiforme: Rowell's syndrome. Int J Dermatol 2007; 46 (Suppl. 3): 30-2.
161. Duarte AF, Mota A, Pereira M et al. Rowell syndrome-case report and review of the literature. Dermatol Online J 2008; 14: 15.
162. Armstrong AW, Fazeli A, Yeh SW et al. Vancomycin-induced linear IgA disease manifesting as bullous erythema multiforme. J Cutan Pathol 2004; 31: 393-7.
163. Burnett JW, Laing JM, Aurelian L. Acute skin eruptions that are positive for herpes simplex virus DNA polymerase in patients with stem cell transplantation: a new manifestation within the erythema multiforme reactive dermatoses. Arch Dermatol 2008; 144: 902-7.
164. Rasmussen JE. Erythema multiforme: a practical approach to recent advances. Pediatr Dermatol 2002; 19: 82-4.
165. Renfro L, Grant-Kels JM, Feder HH et al. Are systemic steroids indicated in the treatment of erythema multiforme? Pediatr Dermatol 1989; 6: 43-50.
166. Martinez AE, Atherton DJ. High-dose systemic corticosteroids can arrest recurrences of severe mucocutaneous erythema multiforme. Pediatr Dermatol 2000; 17: 87-90.
167. Huff JC. Therapy and prevention of erythema multiforme with acyclovir. Semin Dermatol 1988; 7: 212-7.
168. Lemak MA, Duvic M, Bean SF. Oral acyclovir for the prevention of herpes-associated erythema multiforme. J Am Acad Dermatol 1986; 15: 50-4.
169. Tatnall FM, Schofield JK, Leigh I. A double-blind placebo controlled trial of continuous acyclovir therapy in recurrent erythema multiforme. Br J Dermatol 1995; 132: 267-70.
170. Molnar I, Matulis M. Arthritis associated with recurrent erythema multiforme responding to oral acyclovir. Clin Rheumatol 2002; 21: 415-7.
171. Moisson YF, Janier M, Civatte J. Thalidomide for recurrent erythema multiforme. Br J Dermatol 1992; 126: 92-3.
172. Conejo-Mir JS, del Canto S, Muñoz MA et al. Thalidomide as elective treatment in persistent erythema multiforme; report of two cases. J Drugs Dermatol 2003; 2: 40-4.
173. Chen CW, Tsai TF, Chen YF, Hung CM. Persistent erythema multiforme treated with thalidomide. Am J Clin Dermatol 2008; 9: 123-7.
174. Mahendran R, Grant JW, Norris PG. Dapsone-responsive persistent erythema multiforme. Dermatology 2000; 200: 281-2.
175. Davis MD, Rogers RS III, Pittelkow MR. Recurrent erythema multiforme/ Stevens-Johnson syndrome: response to mycophenolate mofetil. Arch Dermatol 2002; 138: 1547-50.
176. Bakis S, Zagarella S. Intermittent oral cyclosporin for recurrent herpes simplexassociated erythema multiforme. Australas J Dermatol 2005; 46: 18-20.
177. Roujeau J-C, Guillaume J-C, Fabre J-D et al. Toxic epidermal necrolysis (Lyell syndrome): incidence and drug aetiology in France, 1981-85. Arch Dermatol 1990; 126: 37-42.
178. Chan H-L, Stern RS, Arndt KA et al. The incidence of erythema multiforme, Stevens-Johnson syndrome, and toxic epidermal necrolysis: a population based study with particular reference to reactions caused by drugs among outpatients. Arch Dermatol 1990; 126: 43-7.
179. Naldi L, Locati F, Marchesi L, Cainelli T. Incidence of toxic epidermal necrolysis in Italy. Arch Dermatol 1990; 126: 1103-4.
180. Strom BL, Carson JL, Halpern AC et al. A population based study of Stevens- Johnson syndrome: incidence and antecedent drug exposures. Arch Dermatol 1991; 127: 831-8.
181. Schöpf E, Stühmer A, Rzany B et al. Toxic epidermal necrolysis and Stevens- Johnson syndrome: an epidemiologic study from West Germany. Arch Dermatol 1991; 127: 839-42.
182. Rzany B, Mockenhaupt M, Baur S et al. Epidemiology of erythema exudativum multiforme majus, Stevens-Johnson syndrome, and toxic epidermal necrolysis in Germany (1990-92): structure and results of a population based registry. J Clin Epidemiol 1996; 49: 769-73.
183. Kaufman DW. Epidemiologic approaches to the study of toxic epidermal necrolysis. J Invest Dermatol 1994; 102: 31S-33S.
184. Stern RS. Utilization of hospital and outpatient care for adverse cutaneous reactions to medications. Pharmacoepidemiol Drug Saf 2005; 14: 677-84.
185. Leenutaphong V, Sivayathorn A, Suthipinittharm P, Sunthopalin P. Stevens- Johnson syndrome and toxic epidermal necrolysis in Thailand. Int J Dermatol 1993; 32: 428-31.
186. Roujeau JC, Kelly JP, Naldi L et al. Medication use and the risk of Stevens- Johnson syndrome or toxic epidermal necrolysis. N Engl J Med 1995; 333: 1600-7.
187. Bastuji-Garin S, Zahedi M, Guillaume JC, Roujeau JC. Toxic epidermal necrolysis (Lyell syndrome) in 77 elderly patients. Age Ageing 1993; 22: 450-6.
188. Porteous DM, Berger TG. Severe cutaneous drug reactions (Stevens-Johnson syndrome and toxic epidermal necrolysis) in human immunodeficiency virus infection. Arch Dermatol 1991; 127: 740-1.
189. Saiag P, Caumes E, Chosidow O et al. Drug-induced toxic epidermal necrolysis (Lyell syndrome) in patients infected with the human immunodeficiency virus. J Am Acad Dermatol 1992; 26: 567-74.
190. Caumes E, Bocquet H, Guermonprez G et al. Adverse cutaneous reactions to pyrimethamine/sulfadiazine and pyrimethamine/clindamycin in patients with AIDS and toxoplasmic encephalitis. Clin Infect Dis 1995; 21: 656-8.
191. Carr A, Tindall B, Penny R, Cooper DA. Patterns of multiple-drug hypersensitivities in HIV-infected patients. AIDS 1993; 7: 1532-3.
192. Merot Y, Gravallese E, Guillén FJ, Murphy GF. Lymphocyte subsets and Langerhans' cells in toxic epidermal necrolysis: report of a case. Arch Dermatol 1986; 122: 455-8.
193. Villada G, Roujeau J-C, Cordonnier C et al. Toxic epidermal necrolysis after bone marrow transplantation: study of nine cases. J Am Acad Dermatol 1990; 23: 870-5.
194. Miyauchi H, Hosokawa H, Akaeda T et al. T-cell subsets in drug-induced toxic epidermal necrolysis: possible pathogenic mechanism induced by CD8 T cells. Arch Dermatol 1991; 127: 851-5.
195. Villada G, Roujeau JC, Clerici T et al. Immunopathology of toxic epidermal necrolysis: keratinocytes, HLA-DR expression, Langerhans' cells, and mononuclear cells: an immunopathologic study of five cases. Arch Dermatol 1992; 128: 50-3.
196. Correia O, Delgado L, Ramos JP et al. Cutaneous T-cell recruitment in toxic epidermal necrolysis: further evidence of CD8 lymphocyte involvement. Arch Dermatol 1993; 129: 466-8.
197. Paquet P, Nikkels A, Arrese JE et al. Macrophages and tumor necrosis factor-α in toxic epidermal necrolysis. Arch Dermatol 1994; 130: 605-8.
198. Leyva L, Torres MJ, Posadas S et al. Anticonvulsant-induced toxic epidermal necrolysis: monitoring the immunologic response. J Allergy Clin Immunol 2000; 105: 157-65.
199. Paquet P, Quatresooz P, Pierard GE. Factor-XIIIa dendrocytes in drug-induced toxic epidermal necrolysis (Lyell's syndrome): paradoxical activation in skin and rarefaction in lymph nodes. Dermatology 2003; 206: 374-8.
200. Caproni M, Torchia D, Schincaglia E et al. The CD40/CD40 ligand system is expressed in the cutaneous lesions of erythema multiforme and Stevens-Johnson syndrome/toxic epidermal necrolysis spectrum. Br J Dermatol 2006; 154: 319-24.
201. Caproni M, Torchia D, Schincaglia E et al. Expression of cytokines and chemokine receptors in the cutaneous lesions of erythema multiforme and Stevens-Johnson syndrome/toxic epidermal necrolysis. Br J Dermatol 2006; 155: 722-8.
202. Quaglino P, Caproni M, Antiga E et al. Serum levels of the Th1 promoter IL-12 and the Th2 chemokine TARC are elevated in erythema multiforme and Stevens- Johnson syndrome/toxic epidermal necrolysis and correlate with soluble Fas ligand expression. An immunoenzymatic study from the Italian Group of Immunopathology. Dermatology 2007; 214: 296-304.
203. Quaglino P, Caproni M, Osella-Abate S et al. Serum interleukin-13 levels are increased in patients with Stevens-Johnson syndrome/toxic epidermal necrolysis but not in those with erythema multiforme. Br J Dermatol 2008; 158: 184-6.
204. Paquet P, Pierard GE. Soluble fractions of tumor necrosis factor-α, interleukin-6 and of their receptors in toxic epidermal necrolysis: a comparison with seconddegree burns. Int J Mol Med 1998; 1: 459-62.
205. Correia O, Delgado L, Roujeau JC et al. Soluble interleukin-2 receptor and interleukin-1α in toxic epidermal necrolysis: a comparative analysis of serum and blister fluid samples. Arch Dermatol 2002; 138: 29-32.
206. Paul C, Wolkenstein P, Adle H et al. Apoptosis as a mechanism of keratinocyte death in toxic epidermal necrolysis. Br J Dermatol 1996; 134: 710-4.
207. Sayama K, Yonehara S, Watanabe Y, Miki Y. Expression of Fas antigen on keratinocytes in vivo and induction of apoptosis in cultured keratinocytes. J Invest Dermatol 1994; 103: 330-4.
208. Abe R, Shimizu T, Shibaki A et al. Toxic epidermal necrolysis and Stevens- Johnson syndrome are induced by soluble fas ligand. Am J Pathol 2003; 162: 1515-20.
209. Murata J, Abe R. Soluble Fas ligand: is it a critical mediator of toxic epidermal necrolysis and Stevens-Johnson syndrome? J Invest Dermatol 2007; 127: 744-5.
210. Marzano AV, Frezzolini A, Caproni M et al. Immunohistochemical expression of apoptotic markers in drug-induced erythema multiforme, Stevens-Johnson syndrome and toxic epidermal necrolysis. Int J Immunopathol Pharmacol 2007; 20: 557-66.
211. Abe R. Toxic epidermal necrolysis and Stevens-Johnson syndrome: soluble Fas ligand involvement in the pathomechanisms of these diseases. J Dermatol Sci 2008; 52: 151-9.
212. Borchers AT, Lee JL, Naguwa SM et al. Stevens-Johnson syndrome and toxic epidermal necrolysis. Autoimmun Rev 2008; 7: 598-605.
213. Murata J, Abe R, Shimizu H. Increased soluble Fas ligand levels in patients with Stevens-Johnson syndrome and toxic epidermal necrolysis preceding skin detachment. J Allergy Clin Immunol 2008; 122: 992-1000.
214. Borchers AT, Lee JL, Naguwa SM et al. Stevens-Johnson syndrome and toxic epidermal necrolysis. Autoimmun Rev 2008; 7: 598-605.
215. Schnyder B, Burkhart C, Schnyder-Frutig K et al. Recognition of sulfamethoxazole and its reactive metabolites by drug-specific CD4 T cells from allergic individuals. J Immunol 2000; 164: 6647-54.
216. Le Cleach L, Delaire S, Boumsell L et al. Blister fluid T lymphocytes during toxic epidermal necrolysis are functional cytotoxic cells which express human natural killer (NK) inhibitory receptors. Clin Exp Immunol 2000; 119: 225-30.
217. Nassif A, Bensussan A, Dorothee G et al. Drug specific cytotoxic T-cells in the skin lesions of a patient with toxic epidermal necrolysis. J Invest Dermatol 2002; 118: 728-33.
218. Friedmann PS, Strickland I, Pirmohamed M, Park BK. Investigation of mechanisms in toxic epidermal necrolysis induced by carbamazepine. Arch Dermatol 1994; 130: 598-604.
219. Lerner LH, Qureshi AA, Reddy BV, Lerner EA. Nitric acid synthase in toxic epidermal necrolysis and Stevens-Johnson syndrome. J Invest Dermatol 2000; 114: 196-9.
220. Paquet P, Nusgens BV, Pierard GE, Lapiere CM. Gelatinases in drug-induced toxic epidermal necrolysis. Eur J Clin Invest 1998; 28: 528-32.
221. Shear NH, Spielberg SP, Grant DM et al. Differences in metabolism of sulfonamides predisposing to idiosyncratic toxicity. Ann Intern Med 1986; 105: 179-84.
222. Yoo JH, Kang DS, Chun WH et al. Anticonvulsant hypersensitivity syndrome with an epoxide hydrolase defect. Br J Dermatol 1999; 140: 181-3.
223. Ueta M, Sotozono C, Inatomi T et al. Association of Fas ligand gene polymorphism with Stevens-Johnson syndrome. Br J Ophthalmol 2008; 92: 989-91.
224. Ueta M, Sotozono C, Inatomi T et al. Association of IL4R polymorphisms with Stevens-Johnson syndrome. J Allergy Clin Immunol 2007; 120: 1457-9.
225. Ueta M, Sotozono C, Inatomi T et al. Association of combined IL-13/IL-4R signaling pathway gene polymorphism with Stevens-Johnson syndrome accompanied by ocular surface complications. Invest Ophthalmol Vis Sci 2008; 49: 1809-13.
226. Ueta M, Sotozono C, Inatomi T et al. Toll-like receptor 3 gene polymorphisms in Japanese patients with Stevens-Johnson syndrome. Br J Ophthalmol 2007; 91: 962-5.
227. Chung WH, Hung SI, Chen YT. Human leukocyte antigens and drug hypersensitivity. Curr Opin Allergy Clin Immunol 2007; 7: 317-23.
228. Gatanaga H, Honda H, Oka S. Pharmacogenetic information derived from analysis of HLA alleles. Pharmacogenomics 2008; 9: 207-14.
229. Chessman D, Kostenko L, Lethborg T et al. Human leukocyte antigen class Irestricted activation of CD8+ T cells provides the immunogenetic basis of a systemic drug hypersensitivity. Immunity 2008; 28: 822-32.
230. Hung SI, Chung WH, Jee SH et al. Genetic susceptibility to carbamazepineinduced cutaneous adverse drug reactions. Pharmacogenet Genomics 2006; 16: 297-306.
231. Man CB, Kwan P, Baum L et al. Association between HLA-B*1502 allele and antiepileptic drug-induced cutaneous reactions in Han Chinese. Epilepsia 2007; 48: 1015-8.
232. Locharernkul C, Loplumlert J, Limotai C et al. Carbamazepine and phenytoin induced Stevens-Johnson syndrome is associated with HLA-B*1502 allele in Thai population. Epilepsia 2008; 49: 2087-91.
233. Lonjou C, Borot N, Sekula P et al. A European study of HLA-B in Stevens- Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugs. Pharmacogenet Genomics 2008; 18: 99-107.
234. Mallal S, Nolan D, Witt C et al. Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir. Lancet 2002; 359: 727-32.
235. Sun HY, Hung CC, Lin PH et al. Incidence of abacavir hypersensitivity and its relationship with HLA-B*5701 in HIV-infected patients in Taiwan. J Antimicrob Chemother 2007; 60: 599-604.
236. Lonjou C, Thomas L, Borot N et al. A marker for Stevens-Johnson syndrome: ethnicity matters. Pharmacogenomics J 2006; 6: 265-8.
237. Alfirevic A, Jorgensen AL, Williamson PR et al. HLA-B locus in Caucasian patients with carbamazepine hypersensitivity. Pharmacogenomics 2006; 7: 813-8.
238. Pirmohamed M, Arbuckle JB, Bowman CE et al. Investigation into the multidimensional genetic basis of drug-induced Stevens-Johnson syndrome and toxic epidermal necrolysis. Pharmacogenomics 2007; 8: 1661-91.
239. Ueta M, Sotozono C, Tokunaga K et al. Strong association between HLA-A*0206 and Stevens-Johnson syndrome in the Japanese. Am J Ophthalmol 2007; 143: 367-8.
240. Ueta M, Tokunaga K, Sotozono C et al. HLA class I and II gene polymorphisms in Stevens-Johnson syndrome with ocular complications in Japanese. Mol Vis 2008; 14: 550-5.
241. Bianchine JR, Macaraeg PVJ, Lasagna L et al. Drugs as aetiologic factors in the Stevens-Johnson syndrome. Am J Med 1968; 44: 390-405.
242. Kauppinen K. Cutaneous reactions to drugs: with special reference to severe mucocutaneous bullous eruptions and sulphonamides. Acta Derm Venereol (Stockh) 1972; 52 (Suppl. 68): 1-89.
243. Böttiger LE, Strandberg I, Westerholm B. Drug-induced febrile mucocutaneous syndrome: with a survey of the literature. Acta Med Scand 1975; 198: 229-33.
244. Ruiz-Maldonado R. Acute disseminated epidermal necrosis types 1, 2, and 3: study of 60 cases. J Am Acad Dermatol 1985; 13: 623-35.
245. Nethercott JR, Choi BC. Erythema multiforme (Stevens-Johnson syndrome): chart review of 123 hospitalized patients. Dermatologica 1985; 171: 383-96.
246. Ting HC, Adam BA. Stevens-Johnson syndrome: a review of 34 cases. Int J Dermatol 1985; 24: 587-91.
247. Leenutaphong V, Sivayathorn A, Suthipinittharm P, Sunthonpalin P. Stevens- Johnson syndrome and toxic epidermal necrolysis in Thailand. Int J Dermatol 1993; 32: 428-31.
248. Gebel K, Hornstein OP. Drug-induced oral erythema multiforme: results of a long-term retrospective study. Dermatologica 1984; 168: 35-40.
249. Stern R, Bigby M. An expanded profile of cutaneous reactions to non-steroidal anti-inflammatory drugs. JAMA 1984; 252: 1433-7.
250. Carrol OM, Bryan PA, Robinson RJ. Stevens-Johnson syndrome associated with long-acting sulfonamides. JAMA 1966; 195: 691-3.
251. Azinge NO, Garrick GA. Stevens-Johnson syndrome (erythema multiforme) following ingestion of trimethoprim-sulfamethoxazole on two separate occasions in the same person: a case report. J Allergy Clin Immunol 1978; 62: 125-6.
252. Aberer W, Stingl G, Wolff K. Stevens-Johnson-Syndrom und toxische epidermale Nekrolyse nach Sulfonamideinahme. Hautarzt 1982; 33: 484-90.
253. Hornstein OP, Ruprecht KW. Fansidar-induced Stevens-Johnson syndrome. N Engl J Med 1982; 307: 1529-30.
254. Miller KD, Lobel HO, Satriale RF et al. Severe cutaneous reactions among American travelers using pyrimethamine-sulfadoxine (Fansidar) for malaria prophylaxis. Am J Trop Med Hyg 1986; 35: 451-8.
255. De Raeve L, Song M, Van Maldergem L. Adverse cutaneous drug reactions in AIDS. Br J Dermatol 1988; 119: 521-3.
256. Porteous DM, Berger TG. Severe cutaneous drug reactions (Stevens-Johnson syndrome and toxic epidermal necrolysis) in human immunodeficiency virus infection. Arch Dermatol 1991; 127: 740-1.
257. van der Ven AJAM, Koopmans PP, Vree TB, van der Meer JWM. Adverse reactions to co-trimoxazole in HIV infection. Lancet 1991; 338: 431-3.
258. Roujeau JC, Kelly JP, Naldi L et al. Medication use and the risk of Stevens- Johnson syndrome or toxic epidermal necrolysis. N Engl J Med 1995; 333: 1600-7.
259. Kaufman DW, Kelly JP. Acetylsalicylic acid and other salicylates in relation to Stevens-Johnson syndrome and toxic epidermal necrolysis. Br J Clin Pharmacol 2001; 51: 174-6.
260. Wetterwald E, Le Cleach L, Michel C et al. Nevirapine-induced overlap Stevens- Johnson syndrome/toxic epidermal necrolysis. Br J Dermatol 1999; 140: 980-2.
261. Metry DW, Lahart CJ, Farmer KL, Hebert AA. Stevens-Johnson syndrome caused by the antiretroviral drug nevirapine. J Am Acad Dermatol 2001; 44 (2 Suppl.): 354-7.
262. Fagot JP, Mockenhaupt M, Bouwes-Bavinck JN et al. Nevirapine and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis. AIDS 2001; 15: 1843-8.
263. Dodi F, Alessandrini A, Camera M et al. Stevens-Johnson syndrome in HIV patients treated with nevirapine: two case reports. AIDS 2002; 16: 1197-8.
264. Bossi P, Roujeau JC, Bricaire F, Caumes E. Stevens-Johnson syndrome associated with abacavir therapy. Clin Infect Dis 2002; 35: 902.
265. Guberman AH, Besag FM, Brodie MJ et al. Lamotrigine-associated rash: risk- benefit considerations in adults and children. Epilepsia 1999; 40: 985-91.
266. Hilas O, Charneski L. Lamotrigine-induced Stevens-Johnson syndrome. Am J Health Syst Pharm 2007; 64: 273-5.
267. Rzany B, Mockenhaupt M, Gehring W, Schöpf E. Stevens-Johnson syndrome after terbinafine therapy. J Am Acad Dermatol 1994; 30: 509.
268. Garty B-Z. Stevens-Johnson syndrome associated with nystatin treatment. Arch Dermatol 1991; 127: 741-2.
269. Bhatia RS. Stevens Johnson syndrome following a single dose of ciprofloxacin. J Assoc Physicians India 1994; 42: 344.
270. Smith HR, Croft AM, Black MM. Dermatological adverse effects with the antimalarial drug mefloquine: a review of 74 published case reports. Clin Exp Dermatol 1999; 24: 249-54.
271. Leckie MJ, Rees RG. Stevens-Johnson syndrome in association with hydroxychloroquine treatment for rheumatoid arthritis. Rheumatology (Oxford) 2002; 41: 473-4.
272. Assier-Bonnet HJ, Aractingi S, Cadranel J et al. Stevens-Johnson syndrome induced by cyclophosphamide: report of two cases. Br J Dermatol 1996; 135: 864-5.
273. Hani N, Casper C, Groth W et al. Stevens-Johnson syndrome-like exanthema secondary to methotrexate histologically simulating acute graft-versus-host disease. Eur J Dermatol 2000; 10: 548-50.
274. Lowndes S, Darby A, Mead G, Lister A. Stevens-Johnson syndrome after treatment with rituximab. Ann Oncol 2002; 13: 1948-50.
275. Mahapatra M, Mishra P, Kumar R. Imatinib-induced Stevens-Johnson syndrome: recurrence after re-challenge with a lower dose. Ann Hematol 2007; 86: 537-8.
276. Dysseleer A, Buysschaert M, Fonck C et al. Acute interstitial nephritis and fatal Stevens-Johnson syndrome after propylthiouracil therapy. Thyroid 2000; 10: 713-6.
277. Lin CC, Wu JC, Huang DF et al. Ranitidine-related Stevens-Johnson syndrome in patients with severe liver diseases: a report of two cases. J Gastroenterol Hepatol 2001; 16: 481-3.
278. Chen KT, Twu SJ, Chang HJ, Lin RS. Outbreak of Stevens-Johnson syndrome/ toxic epidermal necrolysis associated with mebendazole and metronidazole use among Filipino laborers in Taiwan. Am J Public Health 2003; 93: 489-92.
279. Sawamura D, Umeki K. Stevens-Johnson syndrome associated with bezafibrate. Acta Derm Venereol (Stockh) 2000; 80: 7.
280. Knowles S, Gupta AK, Shear NH. The spectrum of cutaneous reactions associated with diltiazem: three cases and a review of the literature. J Am Acad Dermatol 1998; 38: 201-6.
281. Oskay T, Ozçelik T, Kutluay L. Stevens-Johnson Syndrome associated with ramipril. Int J Dermatol 2003; 42: 580-1.
282. January V, Toledano C, Machet L et al. Stevens-Johnson syndrome after sertraline. Acta Derm Venereol (Stockh) 1999; 79: 401.
283. Richard MA, Fiszenson F, Jreissati M et al. Cutaneous adverse effects during selective serotonin reuptake inhibitors therapy: two cases. Ann Dermatol Vénéréol 2001; 128: 759-61.
284. Sanchez I, Garcia-Abujeta JL, Fernandez L et al. Stevens-Johnson syndrome from tetrazepam. Allergol Immunopathol (Madr) 1998; 26: 55-7.
285. Ball R, Ball LK, Wise RP et al. Stevens-Johnson syndrome and toxic epidermal necrolysis after vaccination: reports to the vaccine adverse event reporting system. Pediatr Infect Dis J 2001; 20: 219-23.
286. Mochitomi Y, Inoue A, Kawabata H et al. Stevens-Johnson syndrome caused by a health drink (Eberu) containing ophiopogonis tuber. J Dermatol 1998; 25: 662-5.
287. Hofbauer GF, Burg G, Nestle FO. Cocaine-related Stevens-Johnson syndrome. Dermatology 2000; 201: 258-60.
288. Heng MCY. Drug-induced toxic epidermal necrolysis. Br J Dermatol 1985; 113: 597-60.
289. Fabrizio PJ, McCloshey WW, Jeffrey LP. Drugs causing toxic epidermal necrolysis. Drug Intell Clin Pharmacol 1985; 19: 733-5.
290. Guillaume J-C, Roujeau J-C, Penso D et al. The culprit drugs in 87 cases of toxic epidermal necrolysis (Lyell's syndrome). Arch Dermatol 1987; 123: 1166-70.
291. Ruiz-Maldonado R. Acute disseminated epidermal necrosis types 1, 2 and 3: study of 60 cases. J Am Acad Dermatol 1985; 13: 623-35.
292. Roujeau J-C, Chosidow O, Saiag P, Guillaume J-C. Toxic epidermal necrolysis (Lyell syndrome). J Am Acad Dermatol 1990; 23: 1039-58.
293. Roujeau J-C, Guillaume J-C, Fabre J-D et al. Toxic epidermal necrolysis (Lyell syndrome): incidence and drug aetiology in France, 1981-85. Arch Dermatol 1990; 126: 37-42.
294. Chan H-L, Stern RS, Arndt KA et al. The incidence of erythema multiforme, Stevens-Johnson syndrome, and toxic epidermal necrolysis: a population based study with particular reference to reactions caused by drugs among outpatients. Arch Dermatol 1990; 126: 43-7.
295. Naldi L, Locati F, Marchesi L, Cainelli T. Incidence of toxic epidermal necrolysis in Italy. Arch Dermatol 1990; 126: 1103-4.
296. Strom BL, Carson JL, Halpern AC et al. A population based study of Stevens- Johnson syndrome: incidence and antecedent drug exposures. Arch Dermatol 1991; 127: 831-8.
297. Schöpf E, Stühmer A, Rzany B et al. Toxic epidermal necrolysis and Stevens- Johnson syndrome: an epidemiologic study from West Germany. Arch Dermatol 1991; 127: 839-42.
298. Avakian R, Flowers FP, Araujo OE, Ramos-Caro FA. Toxic epidermal necrolysis: a review. J Am Acad Dermatol 1991; 25: 69-79.
299. Parsons JM. Toxic epidermal necrolysis. Int J Dermatol 1992; 31: 749-68.
300. Paquet P. Les medicaments responsables de necrolyse epidermique toxique (syndrome de Lyell). Thérapie 1993; 48: 133-9.
301. Lyell A. Drug-induced toxic epidermal necrolysis. I. An overview. Clin Dermatol 1993; 11: 491-2.
302. Roujeau JC. Drug-induced toxic epidermal necrolysis. II. Current aspects. Clin Dermatol 1993; 11: 493-500.
303. Leenutaphong V, Sivayathorn A, Suthipinittharm P, Sunthopalin P. Stevens- Johnson syndrome and toxic epidermal necrolysis in Thailand. Int J Dermatol 1993; 32: 428-31.
304. Roujeau JC, Kelly JP, Naldi L et al. Medication use and the risk of Stevens- Johnson syndrome or toxic epidermal necrolysis. N Engl J Med 1995; 333: 1600-7.
305. Sharma VK, Sethuraman G, Minz A. Stevens Johnson syndrome, toxic epidermal necrolysis and SJS-TEN overlap: a retrospective study of causative drugs and clinical outcome. Indian J Dermatol Venereol Leprol 2008; 74: 238-40.
306. Rzany B, Correia O, Kelly JP et al. Risk of Stevens-Johnson syndrome and toxic epidermal necrolysis during first weeks of antiepileptic therapy: a case-control study. Study Group of the International Case Control Study on Severe Cutaneous Adverse Reactions. Lancet 1999; 354: 1033-4.
307. Creamer JD, Whittaker SJ, Kerr-Muir M, Smith NP. Phenytoin-induced toxic epidermal necrolysis: a case report. Clin Exp Dermatol 1996; 21: 116-20.
308. Sterker M, Berrouschot J, Schneider D. Fatal course of toxic epidermal necrolysis under treatment with lamotrigine. Int J Clin Pharmacol Ther 1995; 33: 595-7.
309. Bhushan M, Brooke R, Hewitt-Symonds M et al. Prolonged toxic epidermal necrolysis due to lamotrigine. Clin Exp Dermatol 2000; 25: 349-51.
310. Mockenhaupt M, Messenheimer J, Tennis P, Schlingmann J. Risk of Stevens- Johnson syndrome and toxic epidermal necrolysis in new users of antiepileptics. Neurology 2005; 64: 1134-8.
311. Jick H, Derby LE. A large population based follow-up study of trimethoprimsulfamethoxazole, trimethoprim, and cephalexin for uncommon serious drug toxicity. Pharmacotherapy 1995; 15: 428-32.
312. Romano A, Di Fonso M, Pocobelli D et al. Two cases of toxic epidermal necrolysis caused by delayed hypersensitivity to beta-lactam antibiotics. J Invest Allergol Clin Immunol 1993; 3: 53-5.
313. Stratigos JD, Bartsokas SK, Capetanakis J. Further experiences of toxic epidermal necrolysis incriminating allopurinol, pyrazolone, and derivatives. Br J Dermatol 1972; 86: 564-7.
314. Lee HY, Pang SM, Thamotharampillai T. Allopurinol-induced Stevens-Johnson syndrome and toxic epidermal necrolysis. J Am Acad Dermatol 2008; 59: 352-3.
315. Halevy S, Ghislain PD, Mockenhaupt M et al. Allopurinol is the most common cause of Stevens-Johnson syndrome and toxic epidermal necrolysis in Europe and Israel. J Am Acad Dermatol 2008; 58: 25-32.
316. La Grenade L, Lee L, Weaver J et al. Comparison of reporting of Stevens-Johnson syndrome and toxic epidermal necrolysis in association with selective COX-2 inhibitors. Drug Saf 2005; 28: 917-24.
317. Glasser DL, Burroughs SH. Valdecoxib-induced toxic epidermal necrolysis in a patient allergic to sulfa drugs. Pharmacotherapy 2003; 23: 551-3.
318. Giglio P. Toxic epidermal necrolysis due to administration of celecoxib (Celebrex). South Med J 2003; 96: 320-1.
319. Carstens J, Wendelboe P, Sogaard H, Thestrup-Pedersen K. Toxic epidermal necrolysis and erythema multiforme following therapy with terbinafine. Acta Derm Venereol (Stockh) 1994; 74: 391-2.
320. White SI, Bowen-Jones D. Toxic epidermal necrolysis induced by terbinafine in a patient on long-term antiepileptics. Br J Dermatol 1996; 134: 188-9.
321. Gupta AK, Kopstein JB, Shear NH. Hypersensitivity reaction to terbinafine. J Am Acad Dermatol 1997; 36: 1018-9.
322. Wetterwald E, Le Cleach L, Michel C et al. Nevirapine-induced overlap Stevens-Johnson syndrome/toxic epidermal necrolysis. Br J Dermatol 1999; 140: 980-2.
323. Fagot JP, Mockenhaupt M, Bouwes-Bavinck JN et al. Nevirapine and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis. AIDS 2001; 15: 1843-8.
324. Mallal S, Nolan D, Witt C et al. Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir. Lancet 2002; 359: 727-32.
325. Mallal S, Phillips E, Carosi G et al. HLA-B*5701 screening for hypersensitivity to abacavir. N Engl J Med 2008; 358: 568-79.
326. Roujeau J-C, Guillaume J-C, Fabre J-D et al. Toxic epidermal necrolysis (Lyell syndrome): incidence and drug aetiology in France, 1981-85. Arch Dermatol 1990; 126: 37-42.
327. Stern RS, Chan H-L. Usefulness of case report literature in determining drugs responsible for toxic epidermal necrolysis. J Am Acad Dermatol 1989; 21: 317-22.
328. Nanda A, Kaur S. Drug-induced toxic epidermal necrolysis in developing countries. Arch Dermatol 1990; 126: 125.
329. Mockenhaupt M, Viboud C, Dunant A et al. Stevens-Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs. The EuroSCAR-study. J Invest Dermatol 2008; 128: 35-44.
330. Tham TCK, Allen G, Hayes D et al. Possible association between toxic epidermal necrolysis and ciprofloxacin. Lancet 1991; 338: 522.
331. Moshfeghi M, Mandler HD. Ciprofloxacin-induced toxic epidermal necrolysis. Ann Pharmacother 1993; 27: 467-9.
332. Vidal C, Gonzalez Quintela A, Fuente R. Toxic epidermal necrolysis due to vancomycin. Ann Allergy 1992; 68: 345-7.
333. Hsu SI. Biopsy-proved acute tubulointerstitial nephritis and toxic epidermal necrolysis associated with vancomycin. Pharmacotherapy 2001; 21: 1233-9.
334. Melde SL. Ofloxacin: a probable cause of toxic epidermal necrolysis. Ann Pharmacother 2001; 35: 1388-90.
335. Bédard M-S, Gilbert M. Telithromycin-induced TEN: report of a case. Arch Dermatol 2007; 143: 427-8.
336. Ipuge YA, Rieder HL, Enarson DA. Adverse cutaneous reactions to thiacetazone for tuberculosis treatment in Tanzania. Lancet 1995; 346: 657-60.
337. Azon-Masoliver A, Vilaplana J. Fluconazole-induced toxic epidermal necrolysis in a patient with human immunodeficiency virus infection. Dermatology 1993; 187: 268-9.
338. Taylor B, Duffill M. Toxic epidermal necrolysis from griseofulvin. J Am Acad Dermatol 1988; 19: 565-7.
339. Mion G, Verdon G, Le Gulluche Y et al. Fatal toxic epidermal necrolysis after griseofulvin. Lancet 1989; 2: 1331.
340. Sturchler D, Mittelholzer ML, Kerr L. How frequent are notified severe cutaneous adverse reactions to Fansidar? Drug Saf 1993; 8: 60-8.
341. Wharton JR, Laughlin C, Cockerell CJ. Toxic epidermal necrolysis occurring as a consequence of treatment with foscarnet. Cutis 1999; 63: 333-5.
342. Smith HR, Croft AM, Black MM. Dermatological adverse effects with the antimalarial drug mefloquine: a review of 74 published case reports. Clin Exp Dermatol 1999; 24: 249-54.
343. Murphy M, Carmichael AJ. Fatal toxic epidermal necrolysis associated with hydroxychloroquine. Clin Exp Dermatol 2001; 26: 457-8.
344. Callaly EL, FitzGerald O, Rogers S. Hydroxychloroquine-associated, photoinduced toxic epidermal necrolysis. Clin Exp Dermatol 2008; 33: 572-4.
345. Bodokh I, Lacour JP, Rosenthal E et al. Syndrome de Lyell ou necrolyse epidermique toxique et syndrome de Stevens-Johnson après traitement par fluoxetine. Thérapie 1992; 47: 441.
346. Jonsson GW, Moosa MY, Jeenah FY. Toxic epidermal necrolysis and fluoxetine: a case report. J Clin Psychopharmacol 2008; 28: 93-5.
347. Richard MA, Fiszenson F, Jreissati M et al. Cutaneous adverse effects during selective serotonin reuptake inhibitors therapy: two cases. Ann Dermatol Vénéréol 2001; 128: 759-61.
348. Ahmed R, Eagleton C. Toxic epidermal necrolysis after paroxetine treatment. N Z Med J 2008; 121: 86-9.
349. Lagnaoui R, Ramanampamonjy R, Julliac B et al. Fatal toxic epidermal necrolysis associated with tetrazepam. Therapie 2001; 56: 187-8.
350. Teraki Y, Murota H, Izaki S. Toxic epidermal necrolysis due to zonisamide associated with reactivation of human herpesvirus 6. Arch Dermatol 2008; 144: 232-5.
351. Knowles S, Gupta AK, Shear NH. The spectrum of cutaneous reactions associated with diltiazem: three cases and a review of the literature. J Am Acad Dermatol 1998; 38: 201-6.
352. Al-Shouli S, Abouchala N, Bogusz MJ et al. Toxic epidermal necrolysis associated with high intake of sildenafil and its response to infliximab. Acta Derm Venereol 2005; 85: 534-5.
353. Nagge JJ, Knowles SR, Juurlink DN, Shear NH. Pseudoephedrine-induced toxic epidermal necrolysis. Arch Dermatol 2005; 141: 907-8.
354. Cox NH. Acute disseminated epidermal necrosis due to omeprazole. Lancet 1992; 340: 857.
355. Heaton NR, Edmonds EV, Francis ND et al. Fatal toxic epidermal necrolysis due to lansoprazole. Clin Exp Dermatol 2004; 29: 612-3.
356. Miralles ES, Nunez M, del Olmo N, Ledo A. Ranitidine-related toxic epidermal necrolysis in a patient with idiopathic thrombocytopenic purpura. J Am Acad Dermatol 1995; 32: 133-4.
357. Brunner M, Vardarman E, Goldermann R et al. Toxic epidermal necrolysis (Lyell syndrome) following famotidine administration. Br J Dermatol 1995; 133: 814-5.
358. Tidwell BH, Paterson TM, Burford B. Cimetidine-induced toxic epidermal necrolysis. Am J Health Syst Pharm 1998; 55: 163-4.
359. Pfeiffer CM, Kazenoff S, Rothberg HD. Toxic epidermal necrolysis from atorvastatin. JAMA 1998; 279: 1613-4.
360. Hassikou H, El Haouri M, Tabache F et al. Leflunomide-induced toxic epidermal necrolysis in a patient with rheumatoid arthritis. Joint Bone Spine 2008; 75: 597-9.
361. Hall VC, El-Azhary RA, Bouwhuis S, Rajkumar SV. Dermatologic side effects of thalidomide in patients with multiple myeloma. J Am Acad Dermatol 2003; 48: 548-52.
362. McIvor A. Fatal toxic epidermal necrolysis associated with etretinate (Letter). BMJ 1992; 304: 548.
363. Collins P, Rogers S. The efficacy of methotrexate in psoriasis: a review of 40 cases. Clin Exp Dermatol 1992; 17: 257-60.
364. Primka EJ III, Camisa C. Methotrexate-induced toxic epidermal necrolysis in a patient with psoriasis. J Am Acad Dermatol 1997; 36: 815-8.
365. Ozkan A, Apak H, Celkan T et al. Toxic epidermal necrolysis after the use of high-dose cytosine arabinoside. Pediatr Dermatol 2001; 18: 38-40.
366. Wiener JS, Tucker JA Jr, Walther PJ. Interleukin-2-induced dermatotoxicity resembling toxic epidermal necrolysis. South Med J 1992; 85: 656-9.
367. Lin WL, Lin WC, Yang JY et al. Fatal toxic epidermal necrolysis associated with cetuximab in a patient with colon cancer. J Clin Oncol 2008; 26: 2779-80.
368. Valeyrie-Allanore L, Poulalhon N, Fagot JP et al. Stevens-Johnson syndrome and toxic epidermal necrolysis induced by amifostine during head and neck radiotherapy. Radiother Oncol 2008; 87: 300-3.
369. Halevi A, Ben-Amitai D, Garty BZ. Toxic epidermal necrolysis associated with acetaminophen ingestion. Ann Pharmacother 2000; 34: 32-4.
370. Shoss RG, Rayhanzadeh S. Toxic epidermal necrolysis following measles vaccination. Arch Dermatol 1974; 110: 766-70.
371. Ball R, Ball LK, Wise RP et al. Stevens-Johnson syndrome and toxic epidermal necrolysis after vaccination: reports to the vaccine adverse event reporting system. Pediatr Infect Dis J 2001; 20: 219-23.
372. Kaftori JK, Abraham Z, Gilhar A. Toxic epidermal necrolysis after excretory pyelography: immunologic-mediated contrast medium reaction? Int J Dermatol 1988; 27: 346-7.
373. Lee ML, Chiu IS. Toxic epidermal necrolysis incriminating iopamidol in a child after cardiac catheterization. Intl J Cardiol 2002; 82: 95-7.
374. Searles GE, Tredget EE, Lin AN. Fatal toxic epidermal necrolysis associated with use of terconazole vaginal suppository. J Cutan Med Surg 1998; 3: 85-7.
375. Flórez A, Rosón E, Conde A et al. Toxic epidermal necrolysis secondary to timolol, dorzolamide, and latanoprost eyedrops. J Am Acad Dermatol 2005; 53: 909-11.
376. Radimer GF, Davis J II, Ackerman AB. Fumigant-induced toxic epidermal necrolysis. Arch Dermatol 1974; 110: 103-4.
377. Sachs B, Fischer-Barth W, Erdmann S et al. Anaphylaxis and toxic epidermal necrolysis or Stevens-Johnson syndrome after nonmucosal topical drug application: fact or fiction? Allergy 2007; 62: 877-83.
378. Peck GL, Herzig GP, Elias PM. Toxic epidermal necrolysis in a patient with graftvs- host reaction. Arch Dermatol 1972; 105: 561-9.
379. Villada G, Roujeau J-C, Cordonnier C et al. Toxic epidermal necrolysis after bone marrow transplantation: study of nine cases. J Am Acad Dermatol 1990; 23: 870-5.
380. Mandelcorn R, Shear NH. Lupus-associated toxic epidermal necrolysis: a novel manifestation of lupus? J Am Acad Dermatol 2003; 48: 525-9.
381. Paquet P, Pierard GE. Erythema multiforme and toxic epidermal necrolysis: a comparative study. Am J Dermatopathol 1997; 19: 127-32.
382. Amon RB, Dimond RL. Toxic epidermal necrolysis: rapid differentiation between staphylococcal- and drug-induced disease. Arch Dermatol 1975; 111: 1433-7.
383. Ochsendorf FR, Schöfer H, Milbradt R. Diagnostik des 'Lyell-Syndroms': SSSS oder TEN? Dtschr Med Wochenschr 1988; 113: 860-3.
384. Paquet P, Arrese JE, Beguin Y, Pierard GE. Clinicopathological differential diagnosis of drug-induced toxic epidermal necrolysis (Lyell's syndrome) and acute graft-versus-host reaction. Curr Top Pathol 2001; 94: 49-63.
385. Kauppinen K. Cutaneous reactions to drugs: with special reference to severe mucocutaneous bullous eruptions and sulphonamides. Acta Derm Venereol (Stockh) 1972; 52 (Suppl. 68): 1-89.
386. Böttiger LE, Strandberg I, Westerholm B. Drug-induced febrile mucocutaneous syndrome: with a survey of the literature. Acta Med Scand 1975; 198: 229-33.
387. Ruiz-Maldonado R. Acute disseminated epidermal necrosis types 1, 2, and 3: study of 60 cases. J Am Acad Dermatol 1985; 13: 623-35.
388. Nethercott JR, Choi BC. Erythema multiforme (Stevens-Johnson syndrome): chart review of 123 hospitalized patients. Dermatologica 1985; 171: 383-96.
389. Ting HC, Adam BA. Stevens-Johnson syndrome: a review of 34 cases. Int J Dermatol 1985; 24: 587-91.
390. Ashby DW, Lazar T. Erythema multiforme exudativum major (Stevens-Johnson syndrome). Lancet 1951; i: 1091-5.
391. Rzany B, Hering O, Mockenhaupt M et al. Histopathological and epidemiological characteristics of patients with erythema exudativum multiforme major, Stevens- Johnson syndrome and toxic epidermal necrolysis. Br J Dermatol 1996; 135: 6-11.
392. Hazin R, Ibrahimi OA, Hazin MI, Kimyai-Asadi A. Stevens-Johnson syndrome: pathogenesis, diagnosis, and management. Ann Med 2008; 40: 129-38.
393. Gelfer A, Rivers JK. Long-term follow-up of a patient with eruptive melanocytic nevi after Stevens-Johnson syndrome. Arch Dermatol 2007; 143: 1555-7.
394. Bastuji-Garin S, Rzany B, Stern RS et al. A clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme. Arch Dermatol 1993; 129: 92-6.
395. Roujeau JC. The spectrum of Stevens-Johnson syndrome and toxic epidermal necrolysis: a clinical classification. J Invest Dermatol 1994; 102: 28S-30S.
396. Roujeau JC. Stevens-Johnson syndrome and toxic epidermal necrolysis are severity variants of the same disease which differs from erythema multiforme. J Dermatol 1997; 24: 726-9.
397. Lyell A. Toxic epidermal necrolysis (the scalded skin syndrome): a reappraisal. Br J Dermatol 1979; 100: 69-86.
398. Rasmussen JE. Toxic epidermal necrolysis. Med Clin North Am 1980; 64: 901-20.
399. Chan HL. Observations on drug-induced toxic epidermal necrolysis in Singapore. J Am Acad Dermatol 1984; 10: 973-8.
400. Heng MCY. Drug-induced toxic epidermal necrolysis. Br J Dermatol 1985; 113: 597-60.
401. Revuz J, Penso D, Roujeau J-C et al. Toxic epidermal necrolysis: clinical findings and prognosis factors in 87 patients. Arch Dermatol 1987; 123: 1160-5.
402. Roujeau J-C, Chosidow O, Saiag P, Guillaume J-C. Toxic epidermal necrolysis (Lyell syndrome). J Am Acad Dermatol 1990; 23: 1039-58.
403. Avakian R, Flowers FP, Araujo OE, Ramos-Caro FA. Toxic epidermal necrolysis: a review. J Am Acad Dermatol 1991; 25: 69-79.
404. Lebargy F, Wolkenstein P, Gisselbrecht M et al. Pulmonary complications in toxic epidermal necrolysis: a prospective clinical study. Intensive Care Med 1997; 23: 1237-44.
405. Chosidow O, Delchier J-C, Chaumette M-T et al. Intestinal involvement in druginduced toxic epidermal necrolysis. Lancet 1991; 337: 928.
406. De Felice GP, Caroli R, Auteliano A. Long-term complications of toxic epidermal necrolysis (Lyell's disease): clinical and histopathologic study. Ophthalmologica 1987; 195: 1-6.
407. Sheridan RL, Schulz JT, Ryan CM et al. Long-term consequences of toxic epidermal necrolysis in children. Pediatrics 2002; 109: 74-8.
408. Burns DA, Sarkany I. Junctional naevi following toxic epidermal necrolysis. Clin Exp Dermatol 1978; 3: 323-6.
409. Meneux E, Wolkenstein P, Haddad B et al. Vulvovaginal involvement in toxic epidermal necrolysis: a retrospective study of 40 cases. Obstet Gynecol 1998; 91: 283-7.
410. Roujeau J-C, Phlippoteau C, Koso M et al. Sjögren-like syndrome after druginduced toxic epidermal necrolysis. Lancet 1985; i: 609-11.
411. Schulz JT, Sheridan RL, Ryan CM et al. A 10-year experience with toxic epidermal necrolysis. J Burn Care Rehabil 2000; 21: 199-204.
412. Roujeau J-C, Chosidow O, Saiag P, Guillaume J-C. Toxic epidermal necrolysis (Lyell syndrome). J Am Acad Dermatol 1990; 23: 1039-58.
413. Oplatek A, Brown K, Sen S et al. Long-term follow-up of patients treated for toxic epidermal necrolysis. J Burn Care Res 2006; 27: 26-33.
414. Garcia-Doval I, LeCleach L, Bocquet H et al. Toxic epidermal necrolysis and Stevens-Johnson syndrome: does early withdrawal of causative drugs decrease the risk of death? Arch Dermatol 2000; 136: 323-7.
415. Stern RS. Improving the outcome of patients with toxic epidermal necrolysis and Stevens-Johnson syndrome. Arch Dermatol 2000; 136: 410-1.
416. Honari S, Gibran NS, Heimbach DM et al. Toxic epidermal necrolysis (TEN) in elderly patients. J Burn Care Rehabil 2001; 22: 132-5.
417. McGee T, Munster A. Toxic epidermal necrolysis syndrome: mortality rate reduced with early referral to regional burn center. Plast Reconstr Surg 1998; 102: 1018-22.
418. Westly ED, Wechsler HL. Toxic epidermal necrolysis: granulocytic leukopenia as a prognostic indicator. Arch Dermatol 1984; 120: 721-6.
419. Roujeau JC, Guillaume JC, Revuz J et al. Granulocytes, lymphocytes and toxic epidermal necrolysis. Arch Dermatol 1985; 121: 305.
420. Bastuji-Garin S, Fouchard N, Bertocchi M et al. SCORTEN: a severity-of illness score for toxic epidermal necrolysis. J Invest Dermatol 2000; 115: 149-53.
421. Guégan S, Bastuji-Garin S, Poszepczynska-Guigné E et al. Performance of the SCORTEN during the first five days of hospitalization to predict the prognosis of epidermal necrolysis. J Invest Dermatol 2006; 126: 272-6.
422. Cartotto R, Mayich M, Nickerson D, Gomez M. SCORTEN accurately predicts mortality among toxic epidermal necrolysis patients treated in a burn center. J Burn Care Res 2008; 29: 141-6.
423. Hague JS, Goulding JM, Long TM, Gee BC. Respiratory involvement in toxic epidermal necrolysis portends a poor prognosis that may not be reflected in SCORTEN. Br J Dermatol 2007; 157: 1294-6.
424. Cummings JE, Snyder RR, Kelly EB, Raimer SS. Drug-induced linear immunoglobulin A bullous dermatosis mimicking Stevens-Johnson syndrome: a case report. Cutis 2007; 79: 203-7.
425. Dellavalle RP, Burch JM, Tayal S et al. Vancomycin-associated linear IgA bullous dermatosis mimicking toxic epidermal necrolysis. J Am Acad Dermatol 2003; 48: S56-7.
426. Waldman MA, Black DR, Callen JP. Vancomycin-induced linear IgA bullous disease presenting as toxic epidermal necrolysis. Clin Exp Dermatol 2004; 29: 633-6.
427. Saiag P, Cordoliani F, Roujeau JC et al. Érytheme pigmenté fixe bulleux disséminé simulant un syndrome de Lyell. Ann Dermatol Vénéréol 1987; 114: 1440-2.
428. Baird BJ, De Villez RL. Widespread bullous fixed drug eruption mimicking toxic epidermal necrolysis. Int J Dermatol 1988; 27: 170-4.
429. Guillaume J-C, Roujeau J-C, Penso D et al. The culprit drugs in 87 cases of toxic epidermal necrolysis (Lyell's syndrome). Arch Dermatol 1987; 123: 1166-70.
430. Prendiville JS, Hebert AA, Greenwald MJ et al. Management of Stevens-Johnson syndrome and toxic epidermal necrolysis in children. J Pediatr 1989; 115: 881-7.
431. Roujeau J-C, Chosidow O, Saiag P, Guillaume J-C. Toxic epidermal necrolysis (Lyell syndrome). J Am Acad Dermatol 1990; 23: 1039-58.
432. Avakian R, Flowers FP, Araujo OE, Ramos-Caro FA. Toxic epidermal necrolysis: a review. J Am Acad Dermatol 1991; 25: 69-79.
433. Roujeau JC, Kelly JP, Naldi L et al. Medication use and the risk of Stevens- Johnson syndrome or toxic epidermal necrolysis. N Engl J Med 1995; 333: 1600-7.
434. Rzany B, Correia O, Kelly JP et al. Risk of Stevens-Johnson syndrome and toxic epidermal necrolysis during first weeks of antiepileptic therapy: a case-control study. Study Group of the International Case Control Study on Severe Cutaneous Adverse Reactions. Lancet 1999; 354: 1033-4.
435. Mockenhaupt M, Messenheimer J, Tennis P, Schlingmann J. Risk of Stevens- Johnson syndrome and toxic epidermal necrolysis in new users of antiepileptics. Neurology 2005; 64: 1134-8.
436. Kelly DF, Hope DG. Fatal phenytoin-related toxic epidermal necrolysis: case report. Neurosurgery 1989; 25: 976-8.
437. Wolkenstein P, Chosidow O, Fléchet ML et al. Patch testing in severe cutaneous adverse drug reactions including Stevens-Johnson syndrome and toxic epidermal necrolysis. Contact Dermatitis 1996; 35: 234-6.
438. Roujeau J-C, Albengres E, Moritz SI. Lymphocyte transformation test in druginduced toxic epidermal necrolysis. Int Arch Allergy Appl Immunol 1985; 78: 22-4.
439. Bianchine JR, Macaraeg PVJ, Lasagna L et al. Drugs as aetiologic factors in the Stevens-Johnson syndrome. Am J Med 1968; 44: 390-405.
440. Revuz J, Roujeau J-C, Guillaume J-C et al. Treatment of toxic epidermal necrolysis: Créteil's experience. Arch Dermatol 1987; 123: 1156-8.
441. Roujeau J-C, Revuz J. Intensive care in dermatology. In: Champion RH, Pye RJ, eds. Recent Advances in Dermatology, Vol. 8. Edinburgh: Churchill Livingstone, 1990: 85-99.
442. Smoot EC III. Treatment issues in the care of patients with toxic epidermal necrolysis. Burns 1999; 25: 439-42.
443. Eisen ER, Fish J, Shear NH. Management of drug-induced toxic epidermal necrolysis. J Cutan Med Surg 2000; 4: 96-102.
444. Fritsch PO, Sidoroff A. Drug-induced Stevens-Johnson syndrome/toxic epidermal necrolysis. Am J Clin Dermatol 2000; 1: 349-60.
445. Craven NM. Management of toxic epidermal necrolysis. Hosp Med 2000; 61: 778-81.
446. Hansbrough JF, Muller P, Noordenbos J, Dore C. A 10-year experience with toxic epidermal necrolysis. J Burn Care Rehabil 2001; 22: 97-8.
447. Spies M, Sanford AP, Aili Low JF et al. Treatment of extensive toxic epidermal necrolysis in children. Pediatrics 2001; 108: 1162-8.
448. Palmieri TL, Greenhalgh DG, Saffle JR et al. A multicenter review of toxic epidermal necrolysis treated in US burn centers at the end of the twentieth century. J Burn Care Rehabil 2002; 23: 87-96.
449. Ghislain PD, Roujeau JC. Treatment of severe drug reactions: Stevens-Johnson syndrome, toxic epidermal necrolysis and hypersensitivity syndrome. Dermatol Online J 2002; 8: 5.
450. Descamps V, Tattevin P, Descamps DI. HIV-1 infected patients with toxic epidermal necrolysis: an occupational risk for healthcare workers. Lancet 1999; 353: 1855-6.
451. Chang YS, Huang FC, Tseng SH et al. Erythema multiforme, Stevens-Johnson syndrome, and toxic epidermal necrolysis: acute ocular manifestations, causes, and management. Cornea 2007; 26: 123-9.
452. Gregory DG. The ophthalmologic management of acute Stevens-Johnson syndrome. Ocul Surf 2008; 6: 87-95.
453. Romero-Rangel T, Stavrou P, Cotter J et al. Gas-permeable scleral contact lens therapy in ocular surface disease. Am J Ophthalmol 2000; 130: 25-32.
454. John T, Foulks GN, John ME et al. Amniotic membrane in the surgical management of acute toxic epidermal necrolysis. Ophthalmology 2002; 109: 351-60.
455. Tsai RJ, Li LM, Chen JK. Reconstruction of damaged corneas by transplantation of autologous limbal epithelial cells. N Engl J Med 2000; 343: 86-93.
456. Pianigiani E, Ierardi F, Taddeucci P et al. Skin allograft in the treatment of toxic epidermal necrolysis (TEN). Dermatol Surg 2002; 28: 1173-6.
457. Boorboor P, Vogt PM, Bechara FG et al. Toxic epidermal necrolysis: use of Biobrane or skin coverage reduces pain, improves mobilisation and decreases infection in elderly patients. Burns 2008; 34: 487-92.
458. Lehrer-Bell KA, Kirsner RS, Tallman PG, Kerdel FA. Treatment of the cutaneous involvement in Stevens-Johnson syndrome and toxic epidermal necrolysis with silver nitrate-impregnated dressings. Arch Dermatol 1998; 134: 877-9.
459. Dalli RL, Kumar R, Kennedy P et al. Toxic epidermal necrolysis/Stevens-Johnson syndrome: current trends in management. ANZ J Surg 2007; 77: 671-6.
460. Huang SH, Wu SH, Sun IF et al. AQUACEL Ag in the treatment of toxic epidermal necrolysis (TEN). Burns 2008; 34: 63-6.
461. Halebian PH, Corder VJ, Madden MR et al. Improved burn center survival of patients with toxic epidermal necrolysis managed without corticosteroids. Ann Surg 1986; 204: 503-12.
462. Heimbach DM, Engrav LH, Marvin JA. Toxic epidermal necrolysis: a step forward in treatment. JAMA 1987; 257: 2171-5.
463. Rzany B, Schmitt H, Schöpf E. Toxic epidermal necrolysis in patients receiving glucocorticosteroids. Acta Derm Venereol (Stockh) 1991; 71: 171-2.
464. van der Meer JB, Schuttelaar ML, Toth GG et al. Successful dexamethasone pulse therapy in a toxic epidermal necrolysis (TEN) patient featuring recurrent TEN to oxazepam. Clin Exp Dermatol 2001; 26: 654-6.
465. Kamanabroo D, Schmitz-Landgraf W, Czartnetski BM. Plasmapheresis in severe drug-induced toxic epidermal necrolysis. Arch Dermatol 1985; 121: 1548-9.
466. Egan CA, Grant WJ, Morris SE et al. Plasmapheresis as an adjunct treatment in toxic epidermal necrolysis. J Am Acad Dermatol 1999; 40: 458-61.
467. Bamichas G, Natse T, Christidou F et al. Plasma exchange in patients with toxic epidermal necrolysis. Ther Apher 2002; 6: 225-8.
468. Furubacke A, Berlin G, Anderson C, Sjoberg F. Lack of significant treatment effect of plasma exchange in the treatment of drug-induced toxic epidermal necrolysis? Intensive Care Med 1999; 25: 1307-10.
469. Heng MC, Allen SG. Efficacy of cyclophosphamide in toxic epidermal necrolysis: clinical and pathophysiologic aspects. J Am Acad Dermatol 1991; 25: 778-86.
470. Renfro L, Grant-Kels JM, Daman LA. Drug-induced toxic epidermal necrolysis treated with cyclosporin. Int J Dermatol 1989; 28: 441-4.
471. Arevalo JM, Lorente JA, Gonzalez-Herrada C, Jimenez-Reyes J. Treatment of toxic epidermal necrolysis with cyclosporin A. J Trauma 2000; 48: 473-8.
472. Jarrett P, Rademaker M, Havill J, Pullon H. Toxic epidermal necrolysis treated with cyclosporin and granulocyte colony stimulating factor. Clin Exp Dermatol 1997; 22: 146-7.
473. Wolkenstein P, Latarjet J, Roujeau JC et al. Randomised comparison of thalidomide versus placebo in toxic epidermal necrolysis. Lancet 1998; 352: 1586-9.
474. Namazi MR. Increased mortality in toxic epidermal necrolysis with thalidomide: corroborating or exonerating the pathogenetic role of TNF-alpha? Br J Dermatol 2006; 155: 842-3.
475. Velez A, Moreno JC. Toxic epidermal necrolysis treated with N-acetylcysteine. J Am Acad Dermatol 2002; 46: 469-70.
476. Viard I, Wehril P, Bullani R et al. Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin. Science 1998; 282: 490-3.
477. Stella M, Cassano P, Bollero D et al. Toxic epidermal necrolysis treated with intravenous high-dose immunoglobulins: our experience. Dermatology 2001; 203: 45-9.
478. Paquet P, Jacob E, Damas P, Pierard GE. Treatment of drug-induced toxic epidermal necrolysis (Lyell's syndrome) with intravenous human immunoglobulins. Burns 2001; 27: 652-5.
479. Tristani-Firouzi P, Petersen MJ, Saffle JR et al. Treatment of toxic epidermal necrolysis with intravenous immunoglobulin in children. J Am Acad Dermatol 2002; 47: 548-52.
480. Prins C, Kerdel FA, Padilla RS et al. Toxic epidermal necrolysis-intravenous immunoglobulin: treatment of toxic epidermal necrolysis with high-dose intravenous immunoglobulins-multicenter retrospective analysis of 48 consecutive cases. Arch Dermatol 2003; 139: 26-32.
481. Trent JT, Kirsner RS, Romanelli P, Kerdel FA. Analysis of intravenous immunoglobulin for the treatment of toxic epidermal necrolysis using SCORTEN: the University of Miami Experience. Arch Dermatol 2003; 139: 39-43.
482. Bachot N, Revuz J, Roujeau JC. Intravenous immunoglobulin treatment for Stevens-Johnson syndrome and toxic epidermal necrolysis: a prospective noncomparative study showing no benefit on mortality or progression. Arch Dermatol 2003; 139: 33-6.
483. Wolff K, Tappeiner G. Treatment of toxic epidermal necrolysis: the uncertainty persists but the fog is dispersing. Arch Dermatol 2003; 139: 85-6.
484. Hebert AA, Bogle MA. Intravenous immunoglobulin prophylaxis for recurrent Stevens-Johnson syndrome. J Am Acad Dermatol 2004; 50: 286-8.
485. Lissia M, Figus A, Rubino C. Intravenous immunoglobulins and plasmapheresis combined treatment in patients with severe toxic epidermal necrolysis: preliminary report. Br J Plast Surg 2005; 58: 504-10.
486. Mittmann N, Chan B, Knowles S et al. Intravenous immunoglobulin use in patients with toxic epidermal necrolysis and Stevens-Johnson syndrome. Am J Clin Dermatol 2006; 7: 359-68.
487. French LE, Trent JT, Kerdel FA. Use of intravenous immunoglobulin in toxic epidermal necrolysis and Stevens-Johnson syndrome: our current understanding. Int Immunopharmacol 2006; 6: 543-9.
488. Stella M, Clemente A, Bollero D et al. Toxic epidermal necrolysis (TEN) and Stevens-Johnson syndrome (SJS): experience with high-dose intravenous immunoglobulins and topical conservative approach. A retrospective analysis. Burns 2007; 33: 452-9.
489. French LE. Toxic epidermal necrolysis and Stevens Johnson syndrome: our current understanding. Allergol Int 2006; 55: 9-16.
490. Schneck J, Fagot JP, Sekula P et al. Effects of treatments on the mortality of Stevens-Johnson syndrome and toxic epidermal necrolysis: A retrospective study on patients included in the prospective EuroSCAR Study. J Am Acad Dermatol 2008; 58: 33-40.
491. Majumdar S, Mockenhaupt M, Roujeau J, Townshend A. Interventions for toxic epidermal necrolysis. Cochrane Database Syst Rev 2002; 4: CD001435.
492. Abood GJ, Nickoloff BJ, Gamelli RL. Treatment strategies in toxic epidermal necrolysis syndrome: where are we at? J Burn Care Res 2008; 29: 269-76.
493. Fischer M, Fiedler E, Marsch WC, Wohlrab J. Antitumour necrosis factor-α antibodies (infliximab) in the treatment of a patient with toxic epidermal necrolysis. Br J Dermatol 2002; 146: 707-9.
494. Al-Shouli S, Abouchala N, Bogusz MJ et al. Toxic epidermal necrolysis associated with high intake of sildenafil and its response to infliximab. Acta Derm Venereol 2005; 85: 534-5.
495. Hunger RE, Hunziker T, Buettiker U. Rapid resolution of toxic epidermal necrolysis with anti-TNF-alpha treatment. J Allergy Clin Immunol 2005; 116: 923-4.
496. Meiss F, Helmbold P, Meykadeh N et al. Overlap of acute generalized exanthematous pustulosis and toxic epidermal necrolysis: response to antitumour necrosis factor-alpha antibody infliximab: report of three cases. J Eur Acad Dermatol Venereol 2007; 21: 717-9.
497. Famularo G, Di Dona B, Canzona F et al. Etanercept for toxic epidermal necrolysis. Ann Pharmacother 2007; 41: 1083-4
498. Paquet P, Piérard GE. Intense pulsed light treatment of persistent facial hypermelanosis following drug-induced toxic epidermal necrolysis. Dermatol Surg 2004; 30: 1522-5.
499. Ferrell PB Jr, McLeod HL. Carbamazepine, HLA-B*1502 and risk of Stevens- Johnson syndrome and toxic epidermal necrolysis: US FDA recommendations. Pharmacogenomics 2008; 9: 1543-6.
500. Rauch A, Nolan D, Martin A et al. Prospective genetic screening decreases the incidence of abacavir hypersensitivity reactions in the Western Australian HIV cohort study. Clin Infect Dis 2006; 43: 99-102.
501. Waters LJ, Mandalia S, Gazzard B, Nelson M. Prospective HLA-B*5701 screening and abacavir hypersensitivity: a single centre experience. AIDS 2007; 21: 2533-4.
502. Chui CK, Brumme ZL, Brumme CJ et al. A simple screening approach to reduce B*5701-associated abacavir hypersensitivity on the basis of sequence variation in HIV reverse transcriptase. Clin Infect Dis 2007; 44: 1503-8.
503. Mallal S, Phillips E, Carosi G et al. HLA-B*5701 screening for hypersensitivity to abacavir. N Engl J Med 2008; 358: 568-79.